Highly multiplexed, quantitative protein biomarker profiling (hmqPro)

Introduction

The project will develop a multipurpose, highly multiplexed, quantitative protein profiling (hmqPro) platform that can be adapted to a wide range of applications, particularly biomarker discovery. Biomarkers are a 43 Billion USD market spanning applications in diagnostics, drug discovery & development, personalized medicine, and disease risk assessment.

Methodology

The method comprises an antibody-based profiling of a large number of proteins or protein posttranslational modifications against a large number of samples irrespective of source. Unlike competitor methods, hmqPro does not require platform-specific assay or detection equipment.

Competitive Advantage

Dual multiplexing implemented in a variant method, hmqPro-2D, will make the platform competitive against existing protein profiling methods in:

1. Per-assay cost
2. Flexibility
3. Scalability

Commercialization Routes

The hmqPro platform uniquely complements the technology portfolio of Epigenica AB, and we will chart out two commercialization routes:

1. Service Laboratory Integration: hmqPro will be integrated into a service laboratory offering high-throughput sample-to-result epigenome and protein profiling services to academia, pharma, and biotech industries.
2. Kit Format Distribution: We will package the method in a kit format distributed to R&D and clinical end users.

Conclusion

In summary, the proposed project will deliver a new quantitative protein profiling platform that will have the capacity to impact the biomarker discovery market by combining unique flexibility with high-throughput.